Clinical and Experimental Neuroimmunology

Cover image for Vol. 8 Issue 2

May 2017

Volume 8, Issue 2

Pages 95–173

  1. Issue Information

    1. Top of page
    2. Issue Information
    3. Obituaries
    4. Editorial
    5. New Developments in Neuroimmunology
    6. Commentaries
    7. Focused review series on emerging disorders and unmet medical needs in neuroimmunology
    8. MS/NMO and allied disorders
    9. GBS/CIDP and allied disorders
    10. Immunology and other inflammatory disorders
    11. Tips: Clinical practice and management in neuroimmunological disease
    12. Award Announcement
    13. Congress Report
    1. Issue Information (pages 95–96)

      Version of Record online: 25 MAY 2017 | DOI: 10.1111/cen3.12334

  2. Obituaries

    1. Top of page
    2. Issue Information
    3. Obituaries
    4. Editorial
    5. New Developments in Neuroimmunology
    6. Commentaries
    7. Focused review series on emerging disorders and unmet medical needs in neuroimmunology
    8. MS/NMO and allied disorders
    9. GBS/CIDP and allied disorders
    10. Immunology and other inflammatory disorders
    11. Tips: Clinical practice and management in neuroimmunological disease
    12. Award Announcement
    13. Congress Report
    1. In memoriam: Akihiro Igata, MD, PhD (1928–2016) (page 97)

      Mitsuhiro Osame

      Version of Record online: 6 MAY 2017 | DOI: 10.1111/cen3.12386

    2. In memory of Professor Katsuhiko Hamaguchi (page 98)

      Kyoichi Nomura

      Version of Record online: 5 MAY 2017 | DOI: 10.1111/cen3.12387

  3. Editorial

    1. Top of page
    2. Issue Information
    3. Obituaries
    4. Editorial
    5. New Developments in Neuroimmunology
    6. Commentaries
    7. Focused review series on emerging disorders and unmet medical needs in neuroimmunology
    8. MS/NMO and allied disorders
    9. GBS/CIDP and allied disorders
    10. Immunology and other inflammatory disorders
    11. Tips: Clinical practice and management in neuroimmunological disease
    12. Award Announcement
    13. Congress Report
  4. New Developments in Neuroimmunology

    1. Top of page
    2. Issue Information
    3. Obituaries
    4. Editorial
    5. New Developments in Neuroimmunology
    6. Commentaries
    7. Focused review series on emerging disorders and unmet medical needs in neuroimmunology
    8. MS/NMO and allied disorders
    9. GBS/CIDP and allied disorders
    10. Immunology and other inflammatory disorders
    11. Tips: Clinical practice and management in neuroimmunological disease
    12. Award Announcement
    13. Congress Report
    1. Relationship between Th1 cells and astrocytic connexin 43 gap junctions in multiple sclerosis (pages 101–102)

      Mitsuru Watanabe, Ryo Yamasaki and Jun-ichi Kira

      Version of Record online: 23 MAR 2017 | DOI: 10.1111/cen3.12384

      Thumbnail image of graphical abstract

      Schematic view of our hypothesis that Th1 cells exacerbate the inflammatory process in multiple sclerosis via astrocytic Cx43 downregulation.

  5. Commentaries

    1. Top of page
    2. Issue Information
    3. Obituaries
    4. Editorial
    5. New Developments in Neuroimmunology
    6. Commentaries
    7. Focused review series on emerging disorders and unmet medical needs in neuroimmunology
    8. MS/NMO and allied disorders
    9. GBS/CIDP and allied disorders
    10. Immunology and other inflammatory disorders
    11. Tips: Clinical practice and management in neuroimmunological disease
    12. Award Announcement
    13. Congress Report
  6. Focused review series on emerging disorders and unmet medical needs in neuroimmunology

    1. Top of page
    2. Issue Information
    3. Obituaries
    4. Editorial
    5. New Developments in Neuroimmunology
    6. Commentaries
    7. Focused review series on emerging disorders and unmet medical needs in neuroimmunology
    8. MS/NMO and allied disorders
    9. GBS/CIDP and allied disorders
    10. Immunology and other inflammatory disorders
    11. Tips: Clinical practice and management in neuroimmunological disease
    12. Award Announcement
    13. Congress Report
    1. Review Articles

      You have free access to this content
      Neuromyelitis optica spectrum disorders: Emerging therapies (pages 107–116)

      Manabu Araki and Takashi Yamamura

      Version of Record online: 25 MAY 2017 | DOI: 10.1111/cen3.12394

      Thumbnail image of graphical abstract

      Emerging therapies for acute attacks and prevention of neuromyelitis optica spectrum disorders.

    2. You have free access to this content
      Pathogenesis of human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis (pages 117–128)

      Ryuji Kubota

      Version of Record online: 25 MAY 2017 | DOI: 10.1111/cen3.12395

      Thumbnail image of graphical abstract

      The characteristic of HAM/TSP is the increase in the number of both HTLV-1-infected cells and HTLV-1-specific cytotoxic T lymphocytes in the circulation. The both cells infiltrate the CNS, where HTLV-1 is detected only in infiltrating CD4+ HTLV-1-infected cells, but not in neural cells. The both cells induce an HTLV-1-specific neuroinflammation, causing apoptosis of the neural cells.

  7. MS/NMO and allied disorders

    1. Top of page
    2. Issue Information
    3. Obituaries
    4. Editorial
    5. New Developments in Neuroimmunology
    6. Commentaries
    7. Focused review series on emerging disorders and unmet medical needs in neuroimmunology
    8. MS/NMO and allied disorders
    9. GBS/CIDP and allied disorders
    10. Immunology and other inflammatory disorders
    11. Tips: Clinical practice and management in neuroimmunological disease
    12. Award Announcement
    13. Congress Report
    1. Original Article

      You have full text access to this OnlineOpen article
      Once-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing–remitting multiple sclerosis (pages 129–137)

      Takashi Yamamura, Natalia Ashtamker, David Ladkani, Toshiyuki Fukazawa, Hideki Houzen, Masami Tanaka, Toshiro Miura and Volker Knappertz

      Version of Record online: 23 MAR 2017 | DOI: 10.1111/cen3.12383

      Thumbnail image of graphical abstract

      This phase 2, multi-center, open-label, 52-week study confirmed the well-established GA safety, tolerability and efficacy profile in Japanese MS patients. Patients experienced a 65% reduction in Gd-enhancing MRI lesions and a 42% reduction in annualized relapse rate from pre-treatment levels.

    2. Case Report

      Case of anti-myelin oligodendrocyte glycoprotein antibody-associated demyelinating disease with atopic dermatitis (pages 138–140)

      Kentarou Takei, Mineshige Sato, Masashi Nakamura, Hiroshi Shimizu and Ichiro Nakashima

      Version of Record online: 10 JAN 2017 | DOI: 10.1111/cen3.12365

      We experienced a case of 18 years old female with atopic dermatitis, anti-myelin oligodendrocyte glycoprotein (MOG) antibody-associated acute disseminated encephalomyelitis and without imaging abnormality. After 3days-glucocorticoid therapy, anti-MOG antibody turned to be negative.

  8. GBS/CIDP and allied disorders

    1. Top of page
    2. Issue Information
    3. Obituaries
    4. Editorial
    5. New Developments in Neuroimmunology
    6. Commentaries
    7. Focused review series on emerging disorders and unmet medical needs in neuroimmunology
    8. MS/NMO and allied disorders
    9. GBS/CIDP and allied disorders
    10. Immunology and other inflammatory disorders
    11. Tips: Clinical practice and management in neuroimmunological disease
    12. Award Announcement
    13. Congress Report
    1. Case Report

      Modified method of intravenous immunoglobulin administration for patients with intractable multifocal motor neuropathy: A case report (pages 141–145)

      Akihiro Mukaino, Atsushi Nagaoka, Shunsuke Yoshimura, Hideki Nakajima, Hirokazu Shiraishi, Masakatsu Motomura, Miyuki Morikawa, Susumu Kusunoki, Shunya Nakane, Yukio Ando and Akira Tsujino

      Version of Record online: 4 MAY 2017 | DOI: 10.1111/cen3.12391

      Thumbnail image of graphical abstract

      After intravenous immunoglobulin (IVIg) administration, motor function was improved, but the patient developed muscle weakness only 2 weeks after initial IVIg treatment for multifocal motor neuropathy and his grip strength decreased to 0 kg. Administration of IVIg divided over two separate weeks without changing the total dose per month was dramatically effective. Serum immunoglobulin levels became stable in ≥2000 mg/dL and were associated with muscle strength improvement.

  9. Immunology and other inflammatory disorders

    1. Top of page
    2. Issue Information
    3. Obituaries
    4. Editorial
    5. New Developments in Neuroimmunology
    6. Commentaries
    7. Focused review series on emerging disorders and unmet medical needs in neuroimmunology
    8. MS/NMO and allied disorders
    9. GBS/CIDP and allied disorders
    10. Immunology and other inflammatory disorders
    11. Tips: Clinical practice and management in neuroimmunological disease
    12. Award Announcement
    13. Congress Report
    1. Review Article

      You have free access to this content
      Hypothesis: High salt intake as an inflammation amplifier might be involved in the pathogenesis of neuropsychiatric disorders (pages 146–157)

      Amir Abdoli

      Version of Record online: 2 MAY 2017 | DOI: 10.1111/cen3.12389

      Thumbnail image of graphical abstract

      Excessive salt intake induced severe inflammatory reactions. Inflammations in known to be involve in the pathophysiology of neuropsychiatric disorders. Thus, high salt intake may increase risk of neuropsychiatric disorders through salt derived neural inflammations.

    2. Case Report

      Autoimmune cerebellar ataxia with initial seronegativity and low-titer anti-glutamic acid decarboxylase antibody in the cerebrospinal fluid (pages 158–161)

      Kenichiro Sato, Noritoshi Arai, Taro Bannai, Satoshi Kodama, Aki Omori-Mitsue, Ayumi Hida and Sousuke Takeuchi

      Version of Record online: 4 MAY 2017 | DOI: 10.1111/cen3.12381

      Thumbnail image of graphical abstract

      A case of 34-year-old man presenting with low-titer GAD-Ab positive cerebellar ataxia (AGCA), who on initial evaluation showed elevated GAD-Ab in the CSF but not in the serum, and his serum titer elevated in a delayed manner. It may be indicated that routine screening for adult-onset acute or subacute cerebellar ataxia should include examination for GAD-Ab in both serum and CSF, plus additional follow-up checks for the antibody in the subsequent clinical course.

  10. Tips: Clinical practice and management in neuroimmunological disease

    1. Top of page
    2. Issue Information
    3. Obituaries
    4. Editorial
    5. New Developments in Neuroimmunology
    6. Commentaries
    7. Focused review series on emerging disorders and unmet medical needs in neuroimmunology
    8. MS/NMO and allied disorders
    9. GBS/CIDP and allied disorders
    10. Immunology and other inflammatory disorders
    11. Tips: Clinical practice and management in neuroimmunological disease
    12. Award Announcement
    13. Congress Report
    1. Review Article

      You have free access to this content
      Management of myasthenia gravis in daily practice for general neurologists and healthcare professionals (pages 162–170)

      Kazumasa Yokoyama and Nobutaka Hattori

      Version of Record online: 14 MAY 2017 | DOI: 10.1111/cen3.12390

      Thumbnail image of graphical abstract

      The goal in MG treatment is minimal manifestations (MM) with oral prednisolone (PSL) of 5 mg/day or below, with or without immunosuppressant, and treatment strategies should strive to attain this level as rapidly as possible. In crisis, plasma exchange therapy or IVIg therapy will be applied.

  11. Award Announcement

    1. Top of page
    2. Issue Information
    3. Obituaries
    4. Editorial
    5. New Developments in Neuroimmunology
    6. Commentaries
    7. Focused review series on emerging disorders and unmet medical needs in neuroimmunology
    8. MS/NMO and allied disorders
    9. GBS/CIDP and allied disorders
    10. Immunology and other inflammatory disorders
    11. Tips: Clinical practice and management in neuroimmunological disease
    12. Award Announcement
    13. Congress Report
    1. You have free access to this content
  12. Congress Report

    1. Top of page
    2. Issue Information
    3. Obituaries
    4. Editorial
    5. New Developments in Neuroimmunology
    6. Commentaries
    7. Focused review series on emerging disorders and unmet medical needs in neuroimmunology
    8. MS/NMO and allied disorders
    9. GBS/CIDP and allied disorders
    10. Immunology and other inflammatory disorders
    11. Tips: Clinical practice and management in neuroimmunological disease
    12. Award Announcement
    13. Congress Report

SEARCH

SEARCH BY CITATION